What question did this study set out to answer?

This study investigates the role of GSTM3 in liver fibrosis reversal, focusing on its molecular mechanisms and potential as a biomarker.

May 27, 2026Open Access

GSTM3 Knockdown Promotes Liver Fibrosis Reversal by Inhibiting Hepatic Stellate Cell Activation via PPARγ Signaling

Key Points

This study investigates the role of GSTM3 in liver fibrosis reversal, focusing on its molecular mechanisms and potential as a biomarker.
Analysis of GSTM3 knockdown effects on hepatic stellate cell activation.
Evaluation of PPARγ signaling pathways involved in fibrosis reversal.
Assessment of potential GSTM3 as a biomarker for liver fibrosis.
GSTM3 knockdown significantly reduces hepatic stellate cell activation, promoting fibrosis reversal.
Inhibition of GSTM3 correlates with enhanced PPARγ signaling, suggesting a mechanistic pathway for reversal.
Preliminary findings indicate GSTM3 may serve as a novel biomarker for liver fibrosis reversal.

Abstract

Liver fibrosis is a pivotal and reversible stage in the progression of chronic liver disease. However, the mechanisms underlying fibrosis reversal remain unclear, and effective diagnostic biomarkers are lacking in clinical practice. In this study, we aimed to elucidate the role and molecular mechanisms of glutathione S-transferase Mu 3 (GSTM3) in liver fibrosis reversal, and preliminarily determine whether GSTM3 can serve as a novel biomarker for liver fibrosis reversal.

Demander à l'IA

Bookmark

View Full Paper